| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Restructuring and other charges | 309 | 1,435 | 812 | |
| Research and development | 4,025 | 3,715 | 6,818 | |
| General and administrative | 4,416 | 5,644 | 4,777 | |
| Total operating expenses | 8,750 | 10,794 | 12,407 | |
| Loss from operations | -8,750 | -10,794 | -12,407 | |
| Other income, net | 4,708 | 785 | 412 | |
| Investment income | 1,290 | 1,418 | 1,771 | |
| Total other income, net | 5,998 | 2,203 | 2,183 | |
| Loss before income taxes | -2,752 | -8,591 | -10,224 | |
| Income tax expense | 15 | 28 | 10 | |
| Net loss | -2,767 | -8,619 | -10,234 | |
| Earnings per share, basic | -0.06 | -0.18 | -0.21 | |
| Earnings per share, diluted | -0.06 | -0.18 | -0.21 | |
| Weighted average number of shares outstanding, basic | 48,258,111 | 48,258,111 | 48,258,111 | |
| Weighted average number of shares outstanding, diluted | 48,258,111 | 48,258,111 | 48,258,111 | |
Ikena Oncology, Inc. (IKNA)
Ikena Oncology, Inc. (IKNA)